Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.
GSK appoints Dr Jesse Goodman to the Board as a Non-Executive Director
Dr Jesse Goodman has been appointed to the Board of the Company as a Non-Executive Director and Scientific and Medical Expert
GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis
GSK announced completion of its divesting of rights to ofatumumab for auto-immune indications to Novartis Pharma following reg. approval.
GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets
Two transactions further strengthen HIV pipeline and outlook
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
GSK today announced it has received positive top-line results from the phase III programme investigating sirukumab
Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems
A five-year partnership to fight malaria and improve health in five countries has today been launched by Comic Relief and GSK.
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
GSK announced that EMA has granted marketing authorisation for Nucala® as an add-on treatment for severe refractory eosinophilic asthma
GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK announced that dosing has commenced in a phase III study evaluating sirukumab.
GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris®
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) in patients with systemic lupus erythematosus
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
GSK and Merck to study immunotherapy combination as potential cancer treatment
Phase I human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda®
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV ,Pfizer and Shionogi today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks
GSK profiles innovative R&D portfolio to investors
40 potential new medicines and vaccines offer opportunity to drive long-term performance and deliver new benefits to patients and consumers
Results announcement for the third quarter 2015
Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
GSK today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ successfully met its primary objective
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
GSK announced that its losmapimod phase III study, review of data from part A,3,503 patients did not indicate efficacy against larger part B
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma
GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD
GSK announced positive results from comparing umeclidinium to two available bronchodilator treatments when used by patients with COPD.